Investing Profile

Carlos Solórzano

VCInvestor
Sr. Principal at Section 32
s32.com/team/carlos-solorzanoSan Francisco Bay Area
Photo of Carlos Solórzano, Principal at Section 32

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Deutsche Bank Network
283 CONNECTIONS
University of California, Irvine Network
62 CONNECTIONS
UC Irvine Network
54 CONNECTIONS
University of California, San Francisco Network
39 CONNECTIONS
Private Investment Firm Network
33 CONNECTIONS
cb
Section 32 Principal
Pivotal bioVenture Partners Sr. Associate
$10K - $50K
$25K
$740M
Sr. Principal Section 322022 - Present
NIH Postdoctoral Fellow Private Investment FirmPresent
President - Bay Area Chapter Oxbridge Roundtable SolutionsPresent
Equity Research Associate - Biotechnology Oppenheimer & Co.Present
Assoc Director, Corporate Strategy UltragenyxPresent
Sr. Principal S32Present
Investor in residence Ally Bridge GroupPresent
Principal Ally Bridge GroupPresent
Sr. Associate Pivotal Life Sciences2019 - 2022
Sr. Associate Pivotal bioVenture Partners2019 - 2022
Assoc Director, Corporate Strategy Ultragenyx Pharmaceutical Inc.2018 - 2019
Equity Research Associate - Biotechnology Deutsche Bank2016 - 2018
Equity Research Associate - Biotechnology Oppenheimer & Co. Inc.2015 - 2016
NIH Postdoctoral Fellow University of California, San Francisco2010 - 2015
President - Bay Area Chapter Oxbridge Biotech Roundtable2014 - 2014
Keck Graduate Institute Intensive Summer Business Course
University of California, Irvine Ph.D. Pharmacology and Toxicology
California State Polytechnic University-Pomona B.Sc. Chemical Engineering
UC Irvine Ph.D. Pharmacology and Toxicology
Sign in with Google →
Sign in with Google →